BioXion is the program intelligence platform for biopharma development teams. It reads your CMC, CDMO, quality, analytical, regulatory, and supply chain documents — and gives leadership the visibility to act before programs fall behind.
BioXion doesn’t replace your systems — it gives you a unified view across them. It sits above your QMS, LIMS, and ELN as a program-level intelligence platform, reading data across every function and surfacing what no individual tool can see.
The Program Intelligence Dashboard gives leadership a complete, live view of program health — readiness score, open risk signals, active milestones, and regulatory gaps — without opening a single system or waiting for a status update.
Every program. Every function. Every site. One view — updated in real time, without chasing status reports.
A single number that reflects where your program actually stands — calculated from live data, not PowerPoint slides.
Risk surfaced before it becomes delay. Regulatory gaps flagged before inspection. Decisions made on facts, not instinct.
Users reference their program documents directly within BioXion. The platform reads, interprets, and connects that information — giving leadership a complete intelligence picture without touching your existing infrastructure.
BioXion provides biopharma development teams with an AI-generated CMC plan that adapts to their therapeutic modality, development phase, and regulatory target. Instead of building roadmaps manually from guidance documents, teams get a structured, phase-appropriate plan with regulatory context embedded at every step. This biopharma development software eliminates the risk of missing critical CMC milestones before IND or BLA submission.
Managing multiple contract manufacturing organizations is one of the highest-risk activities in biopharma development. BioXion consolidates CDMO oversight into a single intelligence platform — tracking tech transfer milestones, batch deliverables, audit findings, and partner risk in real time. CDMO management becomes proactive, not reactive.
GMP readiness failures are rarely sudden — they are the result of signals that were present but not connected. BioXion continuously monitors quality events, deviation patterns, and CDMO performance data to surface GMP readiness risks before they escalate. This AI platform for drug development gives quality and operations teams the early warning they need to act.
In biopharma development, a regulatory gap can delay a manufacturing campaign; a CDMO issue can trigger a quality event; a CMC deviation can affect submission readiness. BioXion maps these cross-functional dependencies automatically — giving leadership a connected view of program risk that no individual system or team can produce alone.
BioXion gives your leadership team the visibility to act before programs fall behind. We’re onboarding a selected group of early access partners. Let’s see what your program data reveals.